Altimmune, Inc. Long Term Debt

• Altimmune, Inc. showed an increase of +4,595.1% in Long Term Debt from 2013 to 2025.
• This data is from Altimmune, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2026.
• XBRL data for this metric is available from 2012 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2012: $2.23 million | Q2 2012: $1.98 million | Q3 2012: $1.76 million | Q1 2013: $1.46 million | Q2 2013: $1.22 million | Q3 2013: $974.4 thousand | Q1 2014: $485.4 thousand | Q2 2014: $239.7 thousand | Q4 2016: $526.0 thousand | Q2 2017: $570.5 thousand | Q3 2017: $590.2 thousand | Q2 2025: $14.33 million | Q3 2025: $14.45 million.
• Over the full 3 years of available data (2012 to 2025), Altimmune, Inc.'s Long Term Debt has grown by 1,912.0%.
• Historical annual values: Fiscal year 2025: $34.29 million | Fiscal year 2013: $730.3 thousand | Fiscal year 2012: $1.70 million.
• Data sourced from SEC EDGAR public filings as of August 5, 2026.

Last verified: August 5, 2026